Improving the treatment for women with early-stage endometrial cancer

The feMMe trial aimed to treat obese women with early-stage endometrial cancer less invasively using a mirena, an intra-uterine device, metformin, the most widely used anti-diabetes drug and a weight-loss program.

In this research project, the mirena was loading with metformin, aiming to treat cancer from inside the uterus.  This treatment was far less invasive than a radical hysterectomy and allowed at-risk women to avoid the complications and side effects associated with surgery.  It also provided women with the option to retain their reproductive organs and fertility options.

The feMMe trial has now been completed.  Please find a link to the publication about the results of the feMMe clinical trial – https://doi.org/10.1016/j.ygyno.2021.01.029

If you would like to ask a question about fundraising or give us some feedback, please contact us via the form and let’s chat.

Alternatively, please contact Amy Hyslop, Fundraising and Development Manager on 0488 333 723 or email fundraising@cherish.org.au

You can also direct message us on Facebook, Instagram or Twitter.

If you need professional, confidential support about a gynaecological cancer diagnosis or treatment, please call Cancer Council’s free service on 13 11 20.

Cherish Women’s Cancer Foundation | Registered as Gynaecological Cancer Foundation Ltd | ABN 86 158 553 229